Serina Therapeutics (NYSEAMERICAN:SER) Insider Sells $19,695.00 in Stock

Serina Therapeutics, Inc. (NYSEAMERICAN:SERGet Free Report) insider Randall Moreadith sold 6,500 shares of Serina Therapeutics stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $3.03, for a total value of $19,695.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Randall Moreadith also recently made the following trade(s):

  • On Wednesday, January 28th, Randall Moreadith sold 6,500 shares of Serina Therapeutics stock. The stock was sold at an average price of $3.57, for a total value of $23,205.00.
  • On Thursday, January 22nd, Randall Moreadith sold 2,500 shares of Serina Therapeutics stock. The shares were sold at an average price of $2.95, for a total transaction of $7,375.00.
  • On Wednesday, January 21st, Randall Moreadith sold 2,000 shares of Serina Therapeutics stock. The shares were sold at an average price of $3.00, for a total transaction of $6,000.00.

Serina Therapeutics Stock Down 13.0%

Shares of NYSEAMERICAN SER opened at $2.47 on Friday. Serina Therapeutics, Inc. has a 1 year low of $1.71 and a 1 year high of $7.92.

Serina Therapeutics Company Profile

(Get Free Report)

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.

Read More

Receive News & Ratings for Serina Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Serina Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.